TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04976660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-4
Description: TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
Study: NCT05302804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol Gel
Description: 5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Gel
Description: Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Gel
Description: Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
Study: NCT06435117

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Navigation
Description: CO-CAPTAIN focuses on co-designing and piloting and evaluating the implementation of patient navigation (PN) for primary cancer prevention in people with mental ill-health. Patient Navigators, trained professionals with experience working with people with mental ill-health, will assist people with mental ill-health in gaining access to and utilizing appropriate primary cancer prevention measures offered within the respective healthcare and social system (including smoking cessation and physical activity and nutritional interventions). For this purpose, Patient Navigators will offer regular appointment with participants, apply motivational interviewing and aid in accessing appropriate materials while aiming at empowering participants in taking an active role and making better and more informed decisions regarding their health.
Study: NCT05841069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesiolysis
Description: Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesiolysis
Description: Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.
Study: NCT05527340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
Study: NCT04176978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Patient in this group will receive Rosuvastatin 20mg daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy
Description: Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treat-to-target strategy
Description: Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
Study: NCT05841069

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X-ray examination
Description: Plain X-ray of abdomen (1-4 times) with water insoluble contrast.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: X-ray examination
Description: Plain X-ray of abdomen (1-4 times) with water insoluble contrast.
Study: NCT04937673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Albumin bound paclitaxel+Cisplatin
Description: Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+ Paclitaxel+ Cisplatin
Description: Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks.
Study: NCT05841069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Description: A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.
Study: NCT05077280

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
Study: NCT05659004

Intervention type: BEHAVIORAL
Intervention: Qualitative interview
Description: No intervention
Study: NCT06194721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold intrapulpal anesthesia
Description: Intrapulpal cold local anesthesia at 4-5 c temperature

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature intrapulpal anesthesia
Description: Intrapulpal cold local anesthesia at room temperature
Study: NCT04990531

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-field magnetic resonance imaging
Description: Imaging of lung parenchyma and function by LF-MRI

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Low-field magnetic resonance imaging
Description: Imaging of lung parenchyma and function by LF-MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for diagnostic testing

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample for diagnostic testing
Study: NCT04567420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 4 week cycles
Study: NCT05512637

Intervention type: DIAGNOSTIC_TEST
Intervention: Step 1 - Screening ; Step 2 - Clinical interview
Description: Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process.
Study: NCT04567420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 4 week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Therapy
Description: Standard of Care
Study: NCT03692312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo formulation
Study: NCT04949516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin is discontinued the day after drug-eluting stent implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine is started the day after drug-eluting stent implantation
Study: NCT05979038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients in the intervention arm will take metformin 500mg three times a day
Study: NCT04409470

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood gas sampling from artery and vein
Description: Patients included in this study are treated according to clinical routine. After inclusion, sampling of an arterial blood gas and a venous blood gas is performed simultaneously or as close in time as possible. Because the venous blood gas analysis sample can be taken directly from the patient's peripheral venous catheter, no additional venous puncture is usually required and the additional amount of blood that may be required is approx. 1 ml (the assay requires about 500 µl). In the very rare cases where it is not possible to establish a peripheral venous catheter within a reasonable time, the sample will be acquired from a new venous puncture together with other venous routine samples.
Study: NCT04788459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-eVax
Description: Plasmid DNA Vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-eVax
Description: Plasmid DNA Vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-eVax
Description: Plasmid DNA Vaccine for COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-eVax
Description: Plasmid DNA Vaccine for COVID-19

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator® and EPSGun
Description: IGEA Electroporation Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator® and EPSGun
Description: IGEA Electroporation Device
Study: NCT05859867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of Healthy Nutrition and Physical Activity
Description: Through scheduled and specific activities, enrolled subjects receive information for the promotion of the Mediterranean diet and Mediterranean lifestyle habits, according to the pyramid of the Mediterranean diet. In addition, subjects receive general recommendations about the promotion of regular recreational motor activity, the pyramid of physical activity for pediatric age, and free games appropriate to age. These activities are conducted by professionals in the food (nutritionists) and sports sectors and are aimed in the preparation of simple recipes repeatable at home, and in motor play activities to encourage physical activity. Information regarding clinical, and socio-demographic parameters and family habits will be collected through validated questionnaires.
Study: NCT04248556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care product
Description: Health care product (gel) - to be applied on the participant's skin
Study: NCT06015841

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a solution matching the study vaccine formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-7104.056 at Dose A
Description: The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-7104.056 at Dose B (optional)
Description: The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACI-7104.056 at Dose C (optional)
Description: The study vaccine (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.
Study: NCT05839236

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets
Description: The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
Study: NCT04788459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator® and EPSGun
Description: IGEA Electroporation Device
Study: NCT05498181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Description: sacubitril/valsartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05202002

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video clip
Description: After obtaining written informed consent, participants received a sealed envelope containing a preprinted paper referral to an online website, with a unique identifier.~After entering the online website, participants will be asked to enter the unique identifier they have received into a text box. Only those whose identifiers were predetermined to be associated with the intervention group will receive the intervention.~The intervention is twenty minutes long educational video clip, in which a brief discussion was presented, by an obstetrician, pediatrician, dietitian, and a breastfeeding consultant, each presenting the benefits of breastfeeding for mother and newborn.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No video clip
Description: Participants in this group will receive a unique identifier that belongs to the control group, thus no video clip will be displayed.
Study: NCT05081089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Tablets containing 20/80 mg artemether and 120/480 mg lumefantrine will be administered according to weight as per manufacturer guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Phosphate
Description: The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine with amodiaquine
Description: Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine with amodiaquine
Description: Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: 100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
Study: NCT05509491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A postural awareness program with exercises
Description: A program about postural awareness, bad posture, good posture and their effects on daily life
Study: NCT06011785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silica 12CH
Description: Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
Study: NCT05055830

Intervention type: DRUG
Intervention: The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.
Description: The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.
Study: NCT06139094

Intervention type: DEVICE
Intervention: CardioFlux Magnetocardiography
Description: The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)

Intervention type: DEVICE
Intervention: CardioFlux Magnetocardiography
Description: The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
Study: NCT06274775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Educational video about the nail biopsy procedure
Study: NCT04222257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
Study: NCT06164743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN461 Ophthalmic Solution 1.0%
Description: Topical ocular drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN461 Ophthalmic Solution 0.5%
Description: Topical ocular drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical ocular drug
Study: NCT05127356

Intervention type: DEVICE
Intervention: DIAGNOdent
Description: Laser fluorescence device

Intervention type: DIAGNOSTIC_TEST
Intervention: ICDAS II
Description: International Caries Detection and Assessment System (ICDAS II)
Study: NCT04974411

Intervention type: OTHER
Intervention: infection
Description: this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared

Intervention type: OTHER
Intervention: infection
Description: this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared

Intervention type: OTHER
Intervention: infection
Description: this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared

Intervention type: OTHER
Intervention: sepsis
Description: this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared

Intervention type: OTHER
Intervention: sepsis
Description: this study had two observation cohorts, one that observed sepsis in the presence of infection; the other cohort was monitored during sepsis until septic shock appeared
Study: NCT05502757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable provision
Description: Fresh fruits and vegetables are provided to families at no cost

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable provision
Description: Fresh fruits and vegetables are provided to families at no cost
Study: NCT05460845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
Study: NCT05657444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: intra-arterial tenecteplase during endovascular treatment
Study: NCT05533164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1000mg rituximab in 250ml NaCl 0.9% intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in 250ml NaCl 0.9% intravenously